reSee.it - Related Video Feed

We have administered this type of vaccine to over one billion people, demonstrating its safety. While there is a very low risk of myocarditis, particularly in young men, the risk of developing myocarditis from COVID-19 is actually higher than from the vaccine.

Myocarditis was found more in young men, with rates highest in those aged 16-17. The condition was less common in women and older age groups. Most cases were mild, but some were severe, impacting a person's life. Myocarditis was most common after the second vaccine dose and less frequent in younger children and with subsequent doses. Natural immunity from previous COVID infection was shown to be effective, even more so than two vaccine doses. Combining previous infection with vaccination provided even better protection. The speaker did not take a booster shot. Translation: Myocarditis was more common in young men, especially those aged 16-17. Most cases were mild, but some were severe. The condition was most frequent after the second vaccine dose. Natural immunity from prior COVID infection was found to be effective, even more so than two vaccine doses. Combining previous infection with vaccination provided even better protection. The speaker did not take a booster shot.

Twenty percent of Americans did not take the COVID vaccine because it was not safe enough. The mRNA in the Pfizer and Moderna vaccines has been chemically modified to resist breakdown by enzymes. The mRNA and spike protein are found in the heart and brain, and the spike protein circulates in the blood for six to nine months post-vaccination. The speaker claims the lethal part of the virus circulates in the blood of vaccinated individuals, especially after boosters, and that it is a killer protein. The speaker asserts safety trumps efficacy and objects to claims that vaccines, specifically the COVID-19 vaccine, saved millions of lives. They state that consent forms do not guarantee the vaccine will save lives and that there has never been a prospective, randomized, double-blind, placebo-controlled trial showing that COVID-19 vaccines reduce mortality or hospitalization.

According to the speaker, the COVID vaccine has caused more deaths in the last 8 months than 72 other vaccines combined over the past 30 years. They claim that children are most at risk of suffering from heart attacks due to myocarditis, with a 50% chance of death or requiring a heart transplant within 5 years. The speaker mentions different studies that estimate the likelihood of children getting myocarditis from the vaccine, ranging from 1 in 300 to 1 in 2,700. They argue that the risk of COVID-19 for healthy children is zero, based on studies that found no healthy American child who died from the virus. The speaker also discusses data from Pfizer's trial, highlighting neurological injuries and the case of a girl who is now wheelchair-bound after participating in the trial. They express concern about mandating the vaccine for children based on limited testing.

Myocarditis is a rare side effect of the vaccine, with only 1% of cases resulting in death. However, it is important to note that myocarditis has a high mortality rate of 50% within five years and many deaths within ten years. This poses significant risks for individuals who develop myocarditis after vaccination. The question remains whether the vaccine is necessary for an epidemic that some argue is no more severe than the flu.

The speaker believes that halting mRNA vaccine research and development at BARDA is a tragic, non-science-based mistake. They state that mRNA vaccines saved lives, citing estimates that in 2021, unvaccinated individuals were 12 times more likely to be hospitalized and die, and in 2022, six times more likely. The speaker, a member of the FDA vaccine advisory committee, notes initial concerns about potential serious side effects when the vaccine was rolled out to millions, but these did not materialize. While the vaccine can cause rare myocarditis, it is transient and self-resolving, unlike myocarditis caused by the virus itself, which can lead to hospitalization and death. The speaker emphasizes the technology's potential beyond COVID-19, including applications for cancer and gene therapy.

Myocarditis was most common in young men, with rates as high as 1 in 5000 vaccine recipients. The condition was mostly mild but could have lasting effects. Natural immunity from prior COVID infection was shown to be more protective than two vaccine doses. Combining prior infection with vaccination provided even better protection. The speaker did not take a booster shot.

The speaker discusses a significant increase in myocarditis cases post-vaccination, with studies showing abnormal cardiac scans in vaccinated individuals. They suggest a potential link between mRNA vaccines and heart inflammation, emphasizing the need for long-term monitoring. Research indicates that mRNA and spike proteins can cause myocarditis, posing a concern for all mRNA products. The heart appears to be a vulnerable target due to various factors.

This vaccine has been widely used and is considered safe, with experience in over a billion people. While there is a very low risk of myocarditis, especially in young men, associated with the mRNA technology, the risk of getting myocarditis from COVID-19 itself is higher than the risk from the vaccine.

The speaker questions the effectiveness and safety of COVID vaccines, citing data on high death rates and adverse effects like myocarditis. They criticize the small sample size of Pfizer's clinical trials and argue that the benefits may not outweigh the risks, especially for young people. The speaker emphasizes the need for transparent data and larger studies to make informed decisions about vaccination.

The speaker asks if there is a higher incidence of myocarditis among adolescent males aged 16 to 24 after taking the vaccine. The other speaker responds by saying that the data from the CDC shows that there is actually less myocarditis in people who get the vaccine compared to those who get COVID. The first speaker disagrees and presents six peer-reviewed papers that contradict this claim. They also mention speaking with the president who privately acknowledged the increased risk of myocarditis. The conversation then shifts to discussing the rationality of mandating three vaccines for adolescent boys and the timing of myocarditis after the second dose. The first speaker criticizes the CDC's recommendation to vaccinate individuals who have recovered from COVID and experienced myocarditis. They argue that many countries do not offer the vaccine to children unless they are at risk for severe disease. The first speaker concludes by stating that the risk and benefits of vaccination need to be weighed, and that parents are unlikely to comply with mandatory vaccination for their children.

The speaker asks if there is a higher incidence of myocarditis among boys aged 16 to 24 after taking the vaccine. The other speaker responds that the data from the CDC actually show that there is less risk of myocarditis for those who get the vaccine compared to those who get COVID infection. The first speaker clarifies if they are saying that males in the 16 to 24 age group who take the vaccine have a lower risk of myocarditis than those who contract the disease. The second speaker confirms this.

We have experience with this vaccine in a billion people, showing it is safe. The mRNA vaccine carries a very low risk of myocarditis, especially in young men. However, the risk of myocarditis from COVID is higher than from the vaccine.

In the question, myocarditis is discussed in relation to COVID-19. It has been mentioned for some time that infection with the novel coronavirus can lead to myocarditis, and that in some cases myocarditis can be severe or progress to myocarditis with structural complications. It is noted that myocarditis can also occur after vaccination, but the incidence is small and the symptoms are mild, with most people recovering. The speaker emphasizes that even when myocarditis occurs after vaccination, the risk is small and the condition tends to be mild. The statement asserts that almost all individuals recover from vaccine-associated myocarditis. Therefore, even if people who have received a vaccine develop myocarditis, the situation is not something to be alarmed about. The speaker argues that the benefits of vaccination far outweigh the risks, and that the idea of significant changes or issues related to the vaccine is not supported. The overall conclusion presented is that the risks of myocarditis, whether from infection or vaccination, are outweighed by the benefits of vaccination. Key points reiterated include: - COVID-19 infection can cause myocarditis, sometimes with considerable severity or with structural heart complications. - Myocarditis can also occur after vaccination, but the occurrence is rare and the symptoms are generally mild. - The vast majority of people with vaccine-associated myocarditis recover. - The perceived risk of myocarditis following vaccination should not be a cause for alarm, given that the benefits of vaccination are greater. - There is no indication that anything about the vaccine itself changes in a way that would alter this risk-benefit balance. Overall, the message is that myocarditis is a potential outcome associated with both infection and vaccination, but the frequency is low, the illness is typically mild, recovery is common, and vaccination remains advantageous.

The CDC video discusses the impact of COVID-19 on children and the safety of the vaccine. It emphasizes that although children are less affected by the virus, they can still get seriously ill. The vaccine is deemed safe for children over 6 months, with millions of doses administered and closely monitored for safety. The benefits of vaccination outweigh the risks, particularly the risk of heart inflammation after a COVID infection. The speaker, who plans to vaccinate her own children, encourages parents to consult their child's healthcare provider for more information. The second part of the video addresses the claim that the vaccine increases the risk of heart swelling. The speaker refutes this, stating that investigations found no significant increase in myocarditis cases due to COVID alone, while vaccine-induced myocarditis cases have been reported.

The speaker discusses the potential harm caused by the COVID-19 vaccine, specifically focusing on myocarditis. They state that for every 1 million people vaccinated, there could be 50,000 to 90,000 cases of heart damage. They claim that if someone develops myocarditis, there is a high chance of death within 10 years, with 75% of affected individuals succumbing to the condition. The speaker expresses sympathy towards those affected and highlights the importance of acknowledging the truth and the consequences of vaccine-induced harm.

We have experience with this vaccine in a billion people, showing it is safe. While there is a low risk of myocarditis with mRNA vaccines, the risk from COVID is higher than the vaccine's risk, especially in young men.

This vaccine has been widely used and proven safe in billions of people. The risk of myocarditis, especially in young men, is very low.

Speaker 0 asks Speaker 1 to explain why the vaccine causes myocarditis and pericarditis. Speaker 1 mentions rare reports of myocarditis and pericarditis associated with vaccination but does not provide a clear explanation. Speaker 0 insists on understanding the mechanism and questions why the vaccine is considered safe without addressing the risks. Speaker 2 intervenes, suggesting that Speaker 1 will address the question later. Speaker 1 talks about the benefit-risk ratio and the global recommendation of health authorities. Speaker 0 reiterates the question, to which Speaker 1 agrees to provide a response later. Speaker 2 confirms this agreement.

Before COVID-19, I only encountered two cases of myocarditis in my entire career as a cardiologist. However, now I see two cases per day in the clinic. We have learned that COVID-19 can cause myocarditis, and various organizations conducted screening programs in 2020. These programs found a few cases that met the definition of myocarditis, but none were serious or resulted in hospitalizations or deaths. After the introduction of vaccines, regulatory agencies acknowledged that the vaccines can cause COVID-19 vaccine-induced myocarditis, which can be fatal. It's important for people to understand that there is a risk associated with every vaccine shot they take.

As a cardiologist, the speaker states their role is to fight disease, preserve life, and do no harm. The topic is myocarditis or heart damage from the COVID-19 vaccines. The speaker claims to have examined thousands of patients with this problem, whereas before the pandemic, they state they only had two patients ever with this condition. The speaker references a New England Journal of Medicine paper from Washington University in St. Louis, August 18, 2021, where a 42-year-old man died three days after taking Moderna. They also cite a case from Korea by Choi and colleagues, where a younger man died within eight hours of being in the hospital after Pfizer. The speaker examined images from the Korean case and states the heart appeared "fried with inflammation" and "destroyed." The speaker concludes these cases should have gotten everyone's attention.

The speaker asks Pfizer and Moderna to explain how the COVID-19 vaccine causes myocarditis. The response from the doctors is that the exact mechanism is still being studied, but myocarditis is generally an autoimmune response that can occur after COVID-19 or other infections. The speaker questions if other organs could also be affected by the vaccine, but the doctors explain that ongoing surveillance is in place to monitor potential risks. The speaker expresses concern about the lack of initial disclosure of these risks. The doctors emphasize the importance of preventing COVID-19 and state that the reported rate of myocarditis is around 2-3 per 100,000 doses. The speaker argues that if it can happen to the heart, it could happen to other organs. The conversation ends due to time constraints.

The speaker discusses the increasing awareness and concern surrounding myocarditis as a result of COVID-19 vaccines. They mention that there are now 800 peer-reviewed papers on COVID vaccine-induced myocarditis, with a rate of heart damage at 2.5% in two studies. They explain the pathogenesis of vaccine-induced cardiac arrest and highlight the fatality of this condition. The speaker also mentions cases of athletes and public figures who have experienced myocarditis after vaccination. They express concern about the lingering effects of myocarditis and the recurrence of symptoms. The speaker concludes by discussing the case of a European athlete who experienced a cardiac arrest two years after vaccination, emphasizing the ongoing risk associated with myocarditis.

Speaker 0 asks Speaker 1 to explain the process of how the vaccine causes myocarditis and pericarditis. Speaker 1 mentions rare reports of myocarditis and pericarditis associated with vaccination. Speaker 0 insists on an explanation of the mechanism, but Speaker 1 does not provide a direct answer. Speaker 1 emphasizes that all medicines have benefits and side effects and refers to the benefit-risk ratio. Speaker 0 continues to press for an explanation of the biochemical pathway, but Speaker 1 agrees to provide a response later. The transcript ends with Speaker 2 confirming Speaker 1's agreement to give a further response.

Myocarditis is a small percentage of vaccine deaths, with clotting and bleeding being more common causes. Younger people dying means more life years lost. Vaccines have taken more life years than COVID in the US.